The role of mammographic density in evaluating changes in breast cancer risk

Gynecological Endocrinology

Volumn 21, Issue SUPPL. 1, 2005, Pages 1-5

  Pike, Malcolm C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast cancer; Estrogen; Hormone therapy; Mammographic density; Menopause; Progestogen

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; ESTRONE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TUMOR MARKER;

BODY DENSITY; BREAST BIOPSY; BREAST CANCER; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; ESTROGEN THERAPY; HORMONAL THERAPY; HORMONE DETERMINATION; HUMAN; MAMMOGRAPHY; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; BREAST; CONTRACEPTIVE AGENTS, FEMALE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAMMOGRAPHY; RISK FACTORS;

EID: 25144513843     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590400030038     Document Type: Conference Paper

References (22)

1. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, et al., the Writing Group for the Women's Health Initiative Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253.
2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
3. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast cancer risk following long-term oestrogen- and oestrogen-progestin replacement therapy. Int J Cancer 1999;81:339-344.
4. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Nat Cancer Inst 2000;92:328-332.
5. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
6. Key TJ, Pike MC. The role of estrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer 1988;24:29-43.
7. Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer C. Combined estrogen-progestogen replacement therapy and breast cancer risk. Lancet 1992;340:1044.
8. Berkowitz JE, Gatewood OMB, Goldblum LE, Gayler BW. Hormonal replacement therapy: mammographic manifestations. Radiology 1990;174:199-201.
9. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000;65:659-664.
10. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 1983;303:767-770.
11. Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet 1995;346:883-887.
12. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
13. Ferguson DJ, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer 1981;44:177-181.
14. Dickey RP, Stone SC. Progestational potency of oral contraceptives. Obstet Gynecol 1976;47:106-112.
15. Back DJ, Bates M, Breckenridge AM, Hall JM, MacIver M, Orme ML, Park BK, Rowe PH. The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. Contraception 1981;23:229-239.
16. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-4565.
17. Lee SA, Ross RK, Pike MC. An overview of postmenopausal estrogen-progestin therapy and breast cancer risk (In review).
18. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
19. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Nat Cancer Inst 1995;87:670-675.
20. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Nat Cancer Inst 2003;95:30-37.
21. Ursin G, Palla SL, Reboussin BA, Slone S, Wasillauskas C, Pike MC, Greendale GA. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in Postmenopausal Estrogen/Progstin Interventions (PEPI) Trial. J Clin Oncol 2004;22:2842-2848.
22. Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Nat Cancer Inst 1994;86:431-436.